3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide,
VE 821,
VE-821,
VE821 cpd,
VE-821,
1232410-49-9,
3-Amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide,
VE 821,
VE821,
3-Amino-6-[4-(methylsulfonyl)phenyl]-N-phenyl-2-pyrazinecarboxamide,
CHEMBL1766779,
3-amino-6-(4-methylsulfonylphenyl)-N-phenylpyrazine-2-carboxamide,
DUIHHZKTCSNTGM-UHFFFAOYSA-N,
ATR Inhibitor IV,
MLS006011215,
GTPL8042,
SCHEMBL2483543,
DTXSID60679574,
EX-A530,
CHEBI:124916,
HMS3653B19,
BCP02617,
2788AH,
ABP000791,
BDBM50341733,
MFCD19443686,
s8007,
ZINC68244543,
AKOS025212610,
ACN-029373,
CS-0238,
SB19277,
VE-821/,
NCGC00346444-01,
NCGC00346444-07,
AK322466,
BC638860,
HY-14731,
SC-71109,
SMR004702977,
AB0081615,
VE-821, >=98% (HPLC),
FT-0700135,
SW219507-1,
W-5815,
J-690084,
3-Amino-6-[4-(methylsulfonyl)phenyl]-N-phenyl-2-py,
2-Pyrazinecarboxamide, 3-amino-6-[4-(methylsulfonyl)phenyl]-N-phenyl-,
3-AMINO-6-(4-METHANESULFONYLPHENYL)-N-PHENYLPYRAZINE-2-CARBOXAMIDE,
3-Amino-6-[4-(methanesulfonyl)phenyl]-N-phenylpyrazine-2-carboxamide,
VE821 cpd,
D0G0BJ,
C18H16N4O3S,
A2521,
A11605,
C560580,
3-(3-aminophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione,
ATR serine/threonine protein kinase inhibitors (cancer), Oxford University,
ATR serine/threonine protein kinase inhibitors (cancer), Vertex Pharmaceuticals,